ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      63,729.57
      -0.26%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Aclaris Therapeutics Inc (ACRS)

      7. Aclaris Therapeutics Inc (ACRS) News

      ACRS

      Aclaris Therapeutics (ACRS)

      Aclaris Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ACRS
      DateTimeSourceHeadlineSymbolCompany
      04/30/20247:00AMGlobeNewswire Inc.Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
      04/23/20248:00AMPR Newswire (US)Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive OfficerNASDAQ:ACRSAclaris Therapeutics Inc
      03/05/20245:08PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
      03/05/20245:04PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
      03/05/20245:02PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
      02/27/20247:30AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ACRSAclaris Therapeutics Inc
      02/27/20247:14AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
      02/27/20247:00AMGlobeNewswire Inc.Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
      02/14/20248:32PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACRSAclaris Therapeutics Inc
      02/14/20242:06PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACRSAclaris Therapeutics Inc
      02/13/20242:24PMEdgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ACRSAclaris Therapeutics Inc
      02/05/20247:36PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
      02/05/20247:31PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
      02/05/20247:29PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
      02/05/20247:27PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
      02/05/20244:31PMEdgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ACRSAclaris Therapeutics Inc
      02/05/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
      01/19/20247:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
      01/16/20247:00AMGlobeNewswire Inc.Aclaris Therapeutics Announces Leadership Changes and Strategic Business ReviewNASDAQ:ACRSAclaris Therapeutics Inc
      01/10/20247:00AMGlobeNewswire Inc.Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic DermatitisNASDAQ:ACRSAclaris Therapeutics Inc
      01/03/20244:47PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
      01/03/20244:44PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACRSAclaris Therapeutics Inc
      12/19/20234:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
      12/19/20234:01PMGlobeNewswire Inc.Aclaris Therapeutics Provides Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
      12/05/20234:01PMGlobeNewswire Inc.Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for AlopeciaNASDAQ:ACRSAclaris Therapeutics Inc
      11/13/20237:42AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
      11/13/20237:00AMGlobeNewswire Inc.Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
      11/06/20237:30AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACRSAclaris Therapeutics Inc
      11/06/20237:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACRSAclaris Therapeutics Inc
      11/06/20237:00AMGlobeNewswire Inc.Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate UpdateNASDAQ:ACRSAclaris Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:ACRS